RP13-565O16.1: A Potential Drug Target Or Biomarker (G54967)

Target Name: CT55

NCBI ID: G54967

CT55

RP13-565O16.1: A Potential Drug Target Or Biomarker

CT55 (CT55), also known as RP13-565O16.1, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-protein hybrids, which are characterized by the presence of both RNA and protein components in the same molecule.

The RP13-565O16.1 protein is of particular interest as a potential drug target or biomarker due to its unique structure and the involvement of several disease-related pathways. Its structure consists of a protein domain that is derived from the repetitive region of the T-cell receptor alpha chain, a transmembrane region, and a protein tail.

The protein is involved in several signaling pathways that are critical for various physiological processes in the body. One of the most significant roles of RP13-565O16.1 is in the regulation of cell adhesion, which is a critical process for tissue repair and regeneration.

RP13-565O16.1 is a negative regulator of the Focal Adhesion Protein (FAX), which is a transmembrane protein that is involved in cell-cell adhesion. FAX is a key protein that is involved in several processes in development, including tissue repair and regeneration.

In addition to its role in cell adhesion, RP13-565O16.1 is also involved in the regulation of cell proliferation and apoptosis. It is a negative regulator of the cyclin D1 gene, which encodes the cyclin D1 protein. The cyclin D1 protein is involved in the regulation of cell cycle progression and is a key protein in the G1 phase of the cell cycle.

RP13-565O16.1 is also involved in the regulation of inflammation. It is a negative regulator of the nuclear factor kappa B (NFkB), which is a protein that is involved in the regulation of inflammation and immune responses.

In conclusion, RP13-565O16.1 is a protein that is of particular interest as a potential drug target or biomarker due to its involvement in several disease-related signaling pathways. Its unique structure and multiple functions make it an attractive target for further research and development. Further studies are needed to fully understand the role of RP13-565O16.1 in various biological processes and to explore its potential as a drug or biomarker.

Protein Name: Cancer/testis Antigen 55

The "CT55 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT55 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets